

Adin Bohmiller
Freeport
LD 104

As both a medical cannabis patient and a worker on a cannabis farm, I strongly oppose the harmful overregulation proposed in LD 104. Expanded testing, burdensome track-and-trace requirements, and arbitrary potency limits will raise costs, reduce access, and endanger the survival of small, local producers—hurting both patients and Maine’s local economy.

These unnecessary layers of regulation do not improve safety. Other states with stricter rules still see contaminated products. Meanwhile, small farms already follow rigorous cleanliness, documentation, and quality standards. Adding more compliance requirements only favors large corporations who can absorb the costs and dominate the market.

The current system works. It gives patients access to safe, affordable medicine from trusted local producers. LD 104 threatens that balance and risks turning a community-based program into a corporate monopoly.

Cannabis is agriculture, not Big Pharma. Please reject LD 104 and stand with patients, caregivers, and small farms that built this industry the right way.